Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of BIIB093 in traumatic brain injury
MOH_2019-12-25_008576Phase 2Completed
- Sponsor
- Biogen
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glibenclamide in traumatic brain injury (TBI), sponsored by Biogen. Primary endpoint: Contusion expansion through 96 hours. Started Nov 2019; status: completed.
02
Drugs
glibenclamide
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on MOH_2019-12-25_008576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-25_008576.